SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Maulcoin

Maulcoin is trending as the community celebrates the recovery of its ticker symbol and continues to push for broader visibility while emphasizing their commitment to an organic, long-term project. Investors are actively discussing the potential for a forthcoming chart listing and rallying around a narrative of collective building to differentiate themselves from short-term memecoin scams.

Amazon.com, Inc. is a multinational technology company, which engages in the provision of online retail shopping services. It operates through the following segments: North America, International, and Amazon Web Services (AWS). The North America segment offers retail sale of consumer products, including from sellers, advertising, and subscriptions services through North America-focused online and physical stores. The International segment focuses on retail sale of consumer products, including sellers, advertising, and subscription services through internationally focused online stores. The AWS segment is composed of global sales of computers, storage, databases, and other services for start-ups, enterprises, government agencies, and academic institutions. The company was founded by Jeffrey P. Bezos in July 1994 and is headquartered in Seattle, WA.

Amazon.com Inc.

Amazon.com Inc

Amazon is seeing significant momentum driven by CEO Andy Jassys confirmation of a massive AI infrastructure spend and a $20 billion revenue run rate for its custom silicon business, sparking optimism that it is successfully pivoting toward long-term AI dominance. Community sentiment is increasingly bullish, with traders actively discussing its strategic partnerships with Anthropic and the potential for a major valuation re-rating as AWS scales.

CoreWeave, Inc. engages in the powers of the creation and delivery of the intelligence that drives innovation. It offers a solution used by organizations of all sizes that require sophisticated AI computing, from the largest of enterprises to small, well-funded start-ups. The company was founded by Michael Intrator, Brian Venturo, and Brannin McBee on September 21, 2017 and is headquartered in Livingston, NJ.

CoreWeave Inc. - Ordinary Shares - Class A

CoreWeave Inc

CoreWeave is trending following a significant multi-year cloud infrastructure deal with Anthropic to support its Claude models, signaling sustained demand for high-performance AI compute. While the partnership has fueled bullish sentiment around its expanding roster of major AI clients, traders are simultaneously debating the impact of the company's concurrent upsized debt offering and broader market volatility.

Intuit, Inc. engages in the provision of business and financial management solutions. It operates through the following segments: Small Business and Self-Employed, Consumer, Credit Karma, and ProTax. The Small Business and Self-Employed segment offers QuickBooks financial and business management online services and desktop software, payroll solutions, payment processing solutions, and financing for small businesses. The Consumer segment includes do-it-yourself and assisted TurboTax income tax preparation products and services. The Credit Karma segment serves consumers with a personal finance platform that provides personalized recommendations of credit cards, home, auto and personal loans, and insurance products, and online savings and checking accounts. The ProTax segment refers to the professional accountants in the U.S. and Canada, who are essential to both small business success and tax preparation and filing. The company was founded by Scott D. Cook and Thomas A. Proulx in March 1983 and is headquartered in Mountain View, CA.

Intuit Inc

Intuit is currently trending as investors debate whether the recent sharp sell-off is a fundamental breakdown driven by AI-related disruption or a massive overreaction to bearish sentiment. While community sentiment is heavily divided, many are treating the pullback as a long-term opportunity to buy a profitable, high-margin leader at valuation levels not seen in years, pointing to share buyback acceleration and a strong competitive moat as key catalysts for a potential reversal.

VS Trust - 2x Long VIX Futures ETF

Volatility Shares 2x Long VIX Futures ETF

Investors are actively flocking to UVIX as a hedge against rising geopolitical tensions in the Middle East and concerns over oil supply disruptions following the closure of the Strait of Hormuz. The community is heavily debating whether the current market stability is a temporary lull driven by political rhetoric or a fragile calm before a significant volatility breakout, fueling intense discussion around potential black swan events.

iShares Trust - iShares Expanded Tech-Software Sector ETF

iShares Expanded Tech-Software Sector ETF

The iShares Expanded Tech-Software Sector ETF (IGV) is currently the focal point of a intense debate over whether the sector is experiencing a permanent structural 'SaaSpocalypse' driven by AI disruption or a prime contrarian buying opportunity. While many community members highlight deep valuation compression and signs of institutional accumulation at multi-year lows, others caution that the sector remains highly vulnerable to continued volatility and potential further downside as AI models continue to challenge traditional software business models.

IREN Ltd. is a vertically integrated data center business powering the future of Bitcoin, AI and beyond with renewable energy. It is strategically located in renewable-rich, fiber-connected regions across the US and Canada. IREN’s large-scale, grid-connected facilities are purpose-built for the next generation of power-dense computing applications. The company was founded by Daniel Roberts and William Roberts on November 6, 2018, and is headquartered in Sydney, Australia.

IREN Ltd.

IREN Limited

IREN is seeing heightened community discussion as investors weigh its aggressive infrastructure expansion against ongoing concerns regarding potential equity dilution from its sizable at-the-market offering. The stock is currently being closely monitored for a potential breakout as traders look for news on site energizations and new hyperscaler partnerships to confirm its competitive standing within the evolving AI and data center sector.

Palantir Technologies, Inc. engages in the business of building and deploying software platforms that serve as the central operating systems for its customers. It operates through the Commercial and Government segments. The Commercial segment focuses on customers working in non-government industries. The Government segment is involved in providing services to customers that are the United States government and non-United States government agencies. Its platforms are widely used in areas such as defense, intelligence, healthcare, energy, and financial services, supporting data integration, large-scale analytics, and operational decision-making. The company was founded by Alexander Ceadmon Karp, Peter Andreas Thiel, Stephen Cohen, Joseph Lonsdale, and Nathan Dale Gettings in 2003 and is headquartered in Aventura, FL.

Palantir Technologies Inc - Ordinary Shares - Class A

Palantir Technologies Inc

Palantir Technologies is experiencing heightened volatility and intense social media debate after a high-profile public endorsement from former President Trump, which has fueled a tug-of-war between retail traders banking on a government-backed "narrative tailwind" and bearish investors, including notable figures like Michael Burry, who are focusing on valuation concerns and competitive threats. The active community discussion centers on whether this presidential spotlight will act as a structural catalyst for further government contracts and a short squeeze, or if fundamental pressure from the broader software sector and repricing risks will ultimately dictate the stock's near-term direction.

REalloys, Inc. is engaged in the rebuilding of domestic supply chain resilience for rare earth elements and magnets. It is involved in recycling, mining, oxide production, metallization, alloying, and magnet manufacturing. The company was founded on October 4, 2011 and is headquartered in Boca Raton, FL.

REalloys Inc.

REalloys Inc. is trending as investors focus on its pivot to building a domestic heavy rare earth metallization facility designed to replace Chinese-sourced materials in U.S. defense supply chains. The community is actively debating the company's long-term potential as a critical defense contractor against concerns regarding its pre-revenue status and capital structure.

Sezzle, Inc. engages in the operation of a digital payment platform that enables bank-to-bank transfer of money between consumers and businesses. The company was founded by Charlie G. Youakim, Killian Brackey and Paul V. Paradis on January 4, 2016 and is headquartered in Minneapolis, MN.

Sezzle Inc.

Sezzle is seeing intense market volatility and increased short interest following a board-level shakeup, with the community actively debating whether the resignation of a key board member signals deeper governance issues or a buying opportunity. Traders are heavily focused on the company's strong fundamentals and upcoming earnings as potential catalysts to trigger a short squeeze against a backdrop of ongoing institutional accumulation.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

LLY Launches GLP-1 Pill, Expands Access Through Pharmacy Partnerships

Eli Lilly launches oral GLP-1 pill Foundayo, pairing low-cost access with Amazon and GoodRx partnerships to challenge rivals in the fast-growing obesity market.

Viking Therapeutics to Participate at Upcoming Investor Conferences

Viking Therapeutics to Participate at Upcoming Investor Conferences Viking Therapeutics to Participate at Upcoming Investor Conferences PR Newswire SAN DIEGO, April 10, 2026 SAN DIEGO, April 10, 2026...

MH & Associates Securities Management Corp ADV Buys New Stake in Viking Therapeutics, Inc. $VKTX

MH & Associates Securities Management Corp ADV bought a new stake in Viking Therapeutics, Inc. (NASDAQ:VKTX - Free Report) in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm bought 43,634 shares of the biotechnology company's...

Viking Therapeutics, Inc. (VKTX) Stock Dips While Market Gains: Key Facts

The latest trading day saw Viking Therapeutics, Inc. (VKTX) settling at $33.93, representing a -2.5% change from its previous close.

How to Play Lilly Stock Post Oral Obesity Pill Foundayo's Approval

LLY wins FDA nod for oral obesity pill Foundayo, boosting shares as it eyes billions in sales and a fast catch-up to rivals in the booming GLP-1 market.

Where Will Viking Therapeutics Stock Be in 10 Years?

Key PointsViking Therapeutics has a shot at becoming a leader in the weight-loss market...

LLY Stock Up on GLP-1 Pill Approval: Can it Outpace NVO's Wegovy Pill?

Eli Lilly stock gains on FDA nod for oral obesity drug Foundayo, expanding its portfolio and patient access, setting up a fresh showdown with Novo Nordisk in the GLP-1 market.

Viking Therapeutics, Inc. (NASDAQ:VKTX) Given Average Recommendation of "Moderate Buy" by Brokerages

Shares of Viking Therapeutics, Inc. (NASDAQ:VKTX - Get Free Report) have been given a consensus recommendation of "Moderate Buy" by the fourteen research firms that are covering the firm, Marketbeat reports. One research analyst has rated the stock with a sell rating, four have assigned a hold ra...

<ul class="summary-bullets"><li>CNBC traders said acquisitions are becoming a primary route for drugmakers to enter advanced weight-loss therapy pipelines.</li><li>One trader called it “almost a foregone conclusion” that Viking and Structure could be acquired this year.</li><li>Investor attention remains focused on VK2735, Viking’s dual-agonist obesity therapy advancing through Phase 3 trials.</li></ul>Shares of Viking Therapeutics, Inc. (VKTX) rose over 2% in extended trading on Wednesday after CNBC’s Fast Money said the company could be acquired this year as drugmakers race to expand their presence in the booming GLP-1 obesity market.<a href="https://stocktwits.com/symbol/VKTX">VKTX stock</a> jumped over 1% on Wednesday, marking its second consecutive session of gains.<h2 class="st-heading-2">CNBC Traders Flag Viking As Buyout Target</h2>During the show, traders said pharma companies are turning to acquisitions to secure exposure to advanced weight-loss therapies rather than relying only on internal development.“How do we get in the game? We have to make an acquisition,” one trader said, pointing to Structure Therapeutics (GPCR) and Viking as potential targets and adding, “I think it’s almost a foregone conclusion that those two names at some point get acquired this year.” Viking was also mentioned among CNBC’s Final Trade selections alongside Burlington Stores, Nike, and the S&amp;P 500.<h2 class="st-heading-2">Viking Gains Attention In GLP-1 Deal Wave</h2>Interest in obesity-focused drug developers has intensified following recent momentum across the sector after Eli Lilly secured U.S. approval for its once-daily weight-loss pill Foundayo, just months after Novo Nordisk launched the first oral GLP-1 obesity pill earlier this year.“It just seems like this is an enormous opportunity that is not a lot of money for a big cap pharma or even a medium cap pharma,” one trader on Fast Money said. Recent dealmaking in the market&nbsp;supports their view. Pharma companies have increasingly focused on smaller pipeline acquisitions rather than large megadeals.&nbsp;On Tuesday, Eli Lilly said it will acquire Centessa Pharmaceuticals in a deal valued at up to $7.8 billion. Similar transactions include Biogen acquiring Apellis Pharmaceuticals for $5.6 billion upfront and Merck acquiring Terns Pharmaceuticals for about $5.7 billion.<h2 class="st-heading-2">Viking Expands Obesity Drug Pipeline</h2>Investor focus on Viking has centered on its experimental obesity therapy VK2735, a dual agonist being developed in both injectable and oral formulations. The company recently said enrollment is underway in a late-stage clinical trial evaluating the injectable version of VK2735 in about 1,000 patients with type 2 diabetes who are overweight or obese, with the primary endpoint measuring percentage change in body weight after 78 weeks of treatment compared with placebo.The company expects to have four Phase 3 trials underway this year evaluating VK2735 and plans to advance the oral formulation into late-stage testing following discussions with the U.S. Food and Drug Administration (FDA).Beyond VK2735, Viking is also advancing a separate obesity therapy targeting the amylin pathway, with plans to file an investigational new drug application this quarter and begin early-stage human testing.&nbsp;The drugmaker said earlier this month that&nbsp;it does not need&nbsp;a&nbsp;dominant market share to succeed despite competition from larger pharmaceutical players. “We don't need to get 30% market share,” the company said. “We need to get 5% to 10% share, and we're extremely successful.”<h2 class="st-heading-2">How Do Retail Traders Feel About VKTX?</h2>On Stocktwits, retail sentiment for VKTX has jumped to ‘neutral’ from ‘bullish’ levels a day ago amid a 1,155% surge in message volumes over the past quarter. Watchers have also increased 20% in a year.<figure class="image"><img src="https://news.stocktwits-cdn.com/vktx_ss_png_172d01a9fd.webp" alt="vktx ss.png" width="967" height="143"><figcaption>VKTX sentiment and message volume as of April 2 | Source: Stocktwits</figcaption></figure>One user&nbsp;<a href="https://stocktwits.com/wealthengine6/message/649252701">called</a> VK2735 as the “Next blockbuster oral obesity drug? Likely ahead of $GPCR.”<stembedurl>https://stocktwits.com/wealthengine6/message/649252701</stembedurl>Another user&nbsp;<a href="https://stocktwits.com/507Trader/message/649230524">floated</a> the idea of a possible takeover by AbbVie, saying, “Come on AbbVie, one share of yours for each share of ours and call it a day.”<stembedurl>https://stocktwits.com/507Trader/message/649230524</stembedurl>VKTX stock has risen 38% over the past year.For updates and corrections, email newsroom[at]stocktwits[dot]com.Read Next:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/tesla-stock-dips-overnight-us-demand-weakness-ahead-of-q1-deliveries/cZ7xWlERIF8">Tesla Stock Dips Overnight: US Demand Signals Weakness Ahead Of Closely Watched Q1 Delivery Print</a>

In this photo illustration, a smartphone displays the logo of Viking Therapeutics, Inc., in front of a screen showing the company's latest stock market chart on July 19, 2025 in Chongqing, China. (Photo illustration by Cheng Xin/Getty Images)

VKTX Stock Rises After-Hours: CNBC Flags Viking As Likely Buyout Target This Year As Big Pharma Hunts Next GLP-1 Winner

Viking was also highlighted among CNBC’s Final Trade selections alongside Burlington Stores, Nike and the S&P 500.

Equity

Here's How Much $100 Invested In Viking Therapeutics 10 Years Ago Would Be Worth Today

Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of therapies for metabolic and endocrine disorders. The company was founded by Brian Lian and Michael A. Dinerman on September 24, 2012 and is headquartered in San Diego, CA.

VKTX
Viking Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest VKTX News

VKTXViking Therapeutics Inc